These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30483953)

  • 1. The Effect of Linagliptin versus Metformin Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus.
    Mita T; Hiyoshi T; Yoshii H; Chimori H; Ikeda K; Shimizu M; Kojima Y; Yamamto H; Yasuda D; Sato J; Watada H
    Diabetes Ther; 2019 Feb; 10(1):119-134. PubMed ID: 30483953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study Protocol for the Initial Choice of DPP-4 Inhibitor in Japanese Patients with Type 2 diabetes Mellitus: Effect of Linagliptin on QOL (INTEL-QOL) Trial.
    Mita T; Hiyoshi T; Yoshii H; Chimori H; Ikeda K; Sato J; Watada H
    Diabetes Ther; 2018 Jun; 9(3):1403-1412. PubMed ID: 29744822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of linagliptin versus voglibose on treatment-related quality of life in patients with type 2 diabetes: sub-analysis of the L-STEP study.
    Goto H; Mita T; Fujitani Y; Fujimoto S; Takahashi K; Satoh H; Hirose T; Hiyoshi T; Ai M; Okada Y; Nishimura H; Kuroda H; Matsubara T; Gosho M; Ishii H; Watada H
    Endocr J; 2018 Jun; 65(6):657-668. PubMed ID: 29643323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Multicenter Evaluation of Quality of Life and Treatment Satisfaction in Type 2 Diabetes Patients Receiving Once-Weekly Trelagliptin Versus a Daily Dipeptidyl Peptidase-4 Inhibitor.
    Ishii H; Suzaki Y; Miyata Y; Matsui S
    Diabetes Ther; 2019 Aug; 10(4):1369-1380. PubMed ID: 31214997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials.
    DeFronzo RA; Lee C; Kohler S
    Adv Ther; 2018 Jul; 35(7):1009-1022. PubMed ID: 29949041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
    Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
    Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus.
    Jain RK
    Expert Opin Pharmacother; 2017 Apr; 18(6):545-549. PubMed ID: 28375658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent.
    Tang YZ; Wang G; Jiang ZH; Yan TT; Chen YJ; Yang M; Meng LL; Zhu YJ; Li CG; Li Z; Yu P; Ni CL
    Diabetol Metab Syndr; 2015; 7():91. PubMed ID: 26500706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes.
    Lingvay I; Beetz N; Sennewald R; Schuler-Metz A; Bertulis J; Loley C; Lang B; Lippert C; Lee J; Manning LS; Terada D
    Postgrad Med; 2020 May; 132(4):337-345. PubMed ID: 32366156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linagliptin: a novel methylxanthin based approved dipeptidyl peptidase-4 inhibitor.
    Agrawal R; Jain P; Dikshit SN
    Curr Drug Targets; 2012 Jun; 13(7):970-83. PubMed ID: 22420306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality-of-Life Comparison of Dapagliflozin Versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (J-BOND Study).
    Ishii H; Nakajima H; Kamei N; Niiya T; Hiyoshi T; Hiramori Y; Ohtsu S; Noto T; Shimono D
    Diabetes Ther; 2020 Dec; 11(12):2959-2977. PubMed ID: 33057967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.
    Aronson R
    Curr Med Res Opin; 2015 May; 31(5):901-11. PubMed ID: 25775379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linagliptin/metformin HCl (fixed combination therapy) for the treatment of Type 2 diabetes mellitus.
    Bhargava A
    Expert Rev Endocrinol Metab; 2015 Jul; 10(4):353-363. PubMed ID: 30293498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of initial combination of linagliptin and metformin in patients with type 2 diabetes: A subgroup analysis of Indian patients from a randomized, double-blind, placebo-controlled study.
    Deshmukh V; Sathyanarayana S; Menon S; Patil S; Jones R; Uppal S; Siddiqui K
    Indian J Endocrinol Metab; 2015; 19(2):256-61. PubMed ID: 25729688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes and Renal Dysfunction: a Post-Marketing Surveillance Study.
    Yamamoto F; Ikeda R; Ochiai K; Hirase T; Hayashi N; Okamura T
    Diabetes Ther; 2020 Feb; 11(2):523-533. PubMed ID: 31933070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.
    Graefe-Mody EU; Padula S; Ring A; Withopf B; Dugi KA
    Curr Med Res Opin; 2009 Aug; 25(8):1963-72. PubMed ID: 19552619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial.
    Zeng Z; Yang JK; Tong N; Yan S; Zhang X; Gong Y; Woerle HJ
    Curr Med Res Opin; 2013 Aug; 29(8):921-9. PubMed ID: 23672632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linagliptin/Metformin fixed-dose combination treatment: a dual attack to type 2 diabetes pathophysiology.
    Koliaki C; Doupis J
    Adv Ther; 2012 Dec; 29(12):993-1004. PubMed ID: 23184570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of linagliptin, metformin and lifestyle modification to prevent type 2 diabetes (PRELLIM). A randomized clinical trial.
    Guardado-Mendoza R; Salazar-López SS; Álvarez-Canales M; Farfán-Vázquez D; Martínez-López YE; Jiménez-Ceja LM; Suárez-Pérez EL; Angulo-Romero F; Evia-Viscarra ML; Montes de Oca-Loyola ML; Durán-Pérez EG; Folli F; Aguilar-García A
    Metabolism; 2020 Mar; 104():154054. PubMed ID: 31887309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.